Maillart E, Labauge P, Cohen M, et al. - In this multicentre, open-label, randomized, controlled, crossover study, researchers sought validation for MSCopilot (a software medical device for the self-evaluation of patients with multiple sclerosis (MS) (PwMS), joining four tests: walking, dexterity, cognition and low contrast vision) vs the Multiple Sclerosis Functional Composite (MSFC). Overall 116 PwMS and 69 healthy controls (HCs) were examined. At day 0, all participants were asked to perform MSCopilot and MSFC tests. Reproducibility was evaluated by asking 46 PwMS to perform the same tests at day 30 ± 3. The validation of MSCopilot vs MSFC for the detection of PwMS against HCs, quantified using the area under the curve (AUC), was the primary endpoint. Achievement of the primary endpoint was reported, the non-inferiority of MSCopilot performance to that of MSFC was evident (AUC 0.92 and 0.89 respectively). In this study, MSCopilot was proved as a reliable tool that has confirmed usability in clinical practice for the monitoring of MS-associated disability.